GlassScriptPhysician profile
Roaj Ujjin
NPI 1811987126
$2,072.07
in general payments reported to CMS, 2019-2025
29 companies · $620 in 2025
The $620 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $202 · 2021: $88.91 · 2022: $121 · 2023: $257 · 2024: $226 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $376.14 | 2019-2021 | |
| Novo Nordisk INC | $271.47 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $225.98 | 2019-2025 | |
| Abbott Laboratories | $139.83 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $131.04 | 2022-2025 | Arexvy, Shingrix, Bexsero |
| Dexcom, INC. | $104.92 | 2022-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $89.74 | 2020-2024 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $71.84 | 2019-2025 | Lagevrio |
| Astrazeneca Pharmaceuticals LP | $67.70 | 2019-2023 | Farxiga |
| Exact Sciences Corporation | $63.10 | 2023-2025 | Cologuard Collection Kit |
| Allergan, INC. | $56.58 | 2019 | |
| Axsome Therapeutics, INC. | $55.70 | 2025 | Symbravo, Auvelity |
| Janssen Pharmaceuticals, INC | $52.37 | 2019-2020 | |
| Astellas Pharma US INC | $50.59 | 2025 | Veozah |
| Abbvie INC. | $42.07 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $33.78 | 2025 | General - Pain Management |
| Shield Therapeutics INC | $26.40 | 2025 | |
| Dynavax Technologies Corporation | $24.80 | 2025 | Heplisav-B |
| Novartis Pharmaceuticals Corporation | $21.25 | 2019 | |
| Amarin Pharma, INC. | $19.97 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.66 | 2019 | |
| Idorsia Pharmaceuticals US INC | $18.01 | 2023 | Quviviq |
| Genentech USA, INC. | $17.32 | 2019 | |
| Lifescan, INC. | $16.97 | 2022 | |
| Medtronic Vascular, INC. | $16.94 | 2020 | |
| Sumitomo Pharma America, INC. | $16.81 | 2025 | Gemtesa |
| Genzyme Corporation | $15.71 | 2019 | |
| Eisai INC. | $13.21 | 2020 | |
| Gilead Sciences, INC. | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roaj Ujjin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.